Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Effectiveness of Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
This slide set is based on a comparative effectiveness review (CER) titled Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis, which was developed by the University of Connecticut–Harford Hospital Evidence-based Practice Center for the Agency for Healthcare Research and Quality (AHRQ) under Contract No. 290-2007-10067-I and is available online at www.effectivehealthcare.ahrq.gov.
CERs are comprehensive systematic reviews of the literature that usually compare two or more types of treatment, such as different drugs or adding a second drug, to usual care for the same disease. The literature included in this review was identified in 1) searches for trials and studies that explicitly evaluated the impact of rhGH on outcomes in patients with cystic fibrosis (CF); 2) trials and studies that evaluated the impact of surrogate markers on terminal end points in patients with CF; and 3) trials and studies in which the malignant effects of rhGH were assessed in a CF population or among patients treated for idiopathic short stature or growth-hormone deficiency. Searches were conducted in MEDLINE (starting from 1950) and in the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane Database of Systematic Reviews (both starting from the earliest possible date) through July 2009.
The methods used to develop this CER followed version 1.0 of the Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews published by AHRQ. Available at: http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf.
Your slide tray is being processed.